氨磺必利联合奥氮平对青少年首发精神分裂症患者的临床疗效及对患者认知功能的影响

摘要

目的 探讨氨磺必利联合奥氮平治疗青少年首发精神分裂症的疗效及其对患者认知功能的影响.方法 选取2013年8月~2016年8月金华市第二医院124例诊断为首发精神分裂症的青少年患者,随机分为对照组和观察组,每组62例.对照组给予奥氮平治疗,观察组给予奥氮平联合氨磺必利治疗,分别于治疗前、治疗8周后采用阳性症状与阴性症状量表(positive and negative symptom scale,PANSS)、威斯康星卡片分类测验(wisconsin card sorting Test,WCST)及韦氏记忆量表(wechsler memory scale,WMS)评价患者及临床症状和认知功能情况转好;统计对照组与观察组的临床效果及不良变化.结果 治疗前2组患者的PANSS评分、WCST评分和WMS评分,组间差异无统计学意义;治疗8周后,2组患者PANSS评分、WCST评分和WMS评分均较治疗前明显改善,且观察组上述各项评分改善程度均优于对照组(P<0.05).观察组治疗总有效率93.55%,明显高于对照组的67.74%(χ2=14.49,P<0.05);治疗期间2组患者均无严重不良反应发生.结论 氨磺必利联合奥氮平治疗第一次发作的精神分裂症可有效地改善患者的临床症状和认知功能,同时具有较好的安全性.%Objective To investigate the efficacy of sulforubicin combined with olanzapine in the treatment of adolescents with schizophrenia and to observe its effect on cognitive function.MethodsFrom August 2013 to August 2016, 124 adolescents diagnosed with schizophrenia were randomly divided into control group and observation group,each of 62 cases.The control group was given olanzapine treatment, the observation group was given olanzapine combined with amisulpride treatment.Positive and negative symptom scale (PANSS), Wisconsin Card Sorting Test (WCST) and Wechsler Memory Scale (WMS) were used to evaluate the patient and clinical symptoms and cognitive function after 8 weeks of treatment The clinical effect and adverse changes of two groups were compared.ResultsThe PANSS score, WCST score and WMS score of the two groups were not statistically significant.After 8 weeks of treatment, the PANSS score, WCST score and WMS score of the two groups were significantly higher than those before treatment (P<0.05), and the improvement of the above scores in observation group was better than that of the control group (P<0.05).The total effective rate was 93.55% in the observation group, which was significantly higher than that in the control group (67.74%, χ2=14.49, P<0.05).There was no serious adverse reaction between the two groups.ConclusionThe combination of sulforubicin and olanzapine for the first episode of schizophrenia is very effective in improving the clinical symptoms and cognitive function of patients, and has better safety.